Vivani Medical, Inc. (NASDAQ:VANI – Free Report) – Equities research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for Vivani Medical in a note issued to investors on Thursday, March 13th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.43) per share for the year, down from their previous estimate of ($0.41). HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Vivani Medical’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Vivani Medical’s Q1 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.39) EPS.
Vivani Medical Stock Up 0.9 %
Shares of Vivani Medical stock opened at $1.10 on Monday. The stock has a market cap of $65.16 million, a P/E ratio of -2.44 and a beta of 3.20. Vivani Medical has a 12-month low of $1.03 and a 12-month high of $2.22. The business’s 50 day moving average is $1.16 and its 200-day moving average is $1.22.
Institutional Trading of Vivani Medical
Vivani Medical Company Profile
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Featured Articles
- Five stocks we like better than Vivani Medical
- 3 Best Fintech Stocks for a Portfolio Boost
- Can TikTok Stock Picks Really Make You Rich?
- Overbought Stocks Explained: Should You Trade Them?
- The “Quality” Rotation: Back to Basics Investing
- How to Profit From Growth Investing
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.